From Glucose to Outcomes: The Cardiovascular Prescription Every T2D Patient Deserves

t2diabetesnetwork
14 hours ago
6 min read

Written by Clare Koning, RN, PhD | 6 min read

Key Highlights

✅ Cardiovascular disease (CVD) causes more than 50% of deaths in people with T2D in Canada

✅ People with T2D are 6.5× more likely to experience sudden cardiac death than those without diabetes

✅ The 2024 Diabetes Canada pharmacotherapy update now recommends SGLT2i and GLP-1 RAs for cardiorenal protection regardless of A1C

✅ The SOUL trial (2025) confirmed oral semaglutide reduces major adverse cardiac events (MACE) by 14% in T2D patients with established CVD or chronic kidney disease (CKD)

✅ Fewer than 20% of eligible patients with T2D and high cardiovascular risk receive guideline-directed therapy in real-world practice

✅ Standard ASCVD risk calculators underperform in T2D, nearly half of first MI patients had low or borderline risk scores before their event

Note: In February 2026, the T2D Network published The Shocking Truth About T2D and Heart Disease, a foundational overview of CVD risk in diabetes. This post builds on that evidence with the latest 2025–2026 trial data and a focus on the prescribing gap that evidence alone has not yet closed.

For most of the history of T2D management, the central clinical goal was blood sugar control. The logic was straightforward: elevated glucose damages blood vessels; controlling glucose should prevent that damage; preventing vascular damage should protect the heart, kidneys, and eyes. The landmark UK Prospective Diabetes Study reinforced this model. It became the framework for a generation of diabetes care.

Then the ACCORD, ADVANCE, and VADT trials complicated it. Intensive glycemic control, driving HbA1c below 6.5%, did not reliably reduce cardiovascular events, and in some cases increased mortality.

The field was left with a difficult question: if glucose control wasn't enough, what would protect the heart? The answer arrived between 2015 and 2025, trial by trial.

https://www.youtube.com/watch?v=t8FF6OESqVQ

A Decade of Evidence That Changed Cardiovascular Outcomes

In 2015, the EMPA-REG OUTCOME trial reported that empagliflozin, an SGLT2 inhibitor developed as a glucose-lowering agent, reduced cardiovascular death by 38% and hospitalization for heart failure by 35% compared to placebo, in patients with T2D and established cardiovascular disease. The magnitude of the effect was striking. The speed of onset, benefits appeared within months, far too quickly to be explained by glycemic improvement, was even more striking. Something else was happening.

Over the next decade, the evidence accumulated across dozens of trials:

LEADER (2016): Liraglutide reduced major adverse cardiac events (MACE) by 13% in patients with T2D and high CVD risk
SUSTAIN-6 (2016): Subcutaneous semaglutide reduced MACE by 26%
DECLARE-TIMI 58 (2018): Dapagliflozin reduced hospitalization for heart failure by 27%
CREDENCE (2019): Canagliflozin reduced the composite kidney outcome by 30% in patients with T2D and CKD
DAPA-HF (2019): Dapagliflozin reduced worsening heart failure and cardiovascular death by 26%, including in patients without diabetes
EMPEROR-Reduced (2020): Empagliflozin reduced cardiovascular death or hospitalization for heart failure by 25%

The 2025 comprehensive review in Frontiers in Endocrinology synthesizes this evidence clearly: SGLT2 inhibitors and GLP-1 receptor agonists have demonstrated cardiovascular and renal protection in T2D that is largely independent of glucose control, operating through mechanisms including natriuresis, reduction in cardiac preload and afterload, direct anti-inflammatory effects, and mitigation of atherosclerotic plaque progression.

The SOUL Trial: Closing the Loop on Oral Therapy

The most recent and clinically significant addition to this evidence base is the SOUL trial, published in 2025. SOUL evaluated once-daily oral semaglutide, the tablet formulation of the GLP-1 receptor agonist already familiar to prescribers, in 9,650 patients with T2D and established atherosclerotic CVD, CKD, or both, over a median follow-up of 49.5 months.

Oral semaglutide reduced the risk of MACE by 14% compared to placebo (HR 0.86; 95% CI 0.77–0.96; p=0.006), primarily driven by reductions in non-fatal MI and major adverse limb events. The finding is clinically important for two reasons.

First, it confirms cardiovascular protection for an oral formulation, which may be meaningful for patients who are hesitant about or ineligible for injectable therapy.

Second, 27% of participants were already receiving SGLT2 inhibitor therapy at baseline, and SOUL demonstrated complementary benefit on top of background SGLT2i. The two drug classes appear to protect the heart through different mechanisms, and using both in high-risk patients may be additive. A 2025 systematic review in PMC evaluating SGLT2i plus GLP-1 RA combination therapy confirmed cardiometabolic benefits with an acceptable safety profile.

What Canadian Guidelines Now Say

The 2024 update to the Diabetes Canada Clinical Practice Guidelines: Chapter 13 represents the clearest statement yet of where Canadian diabetes care has landed. The key clinical message is a fundamental shift in framing:

SGLT2 inhibitors and GLP-1 receptor agonists should be used for cardiorenal protection in people with high cardiovascular risk, heart failure, or chronic kidney disease, and should be initiated if these comorbidities are present at diagnosis or develop over time, even if A1C is at target.

This is an outcomes-first framework. It decouples prescribing from glycemia and ties it directly to organ protection. The practical implication: a patient whose HbA1c is 6.8% on metformin, who also has heart failure and CKD, should be on an SGLT2 inhibitor regardless of whether their glucose control appears satisfactory.

The 2022 Canadian Cardiovascular Society cardiorenal guideline, updated with subsequent trial data, reinforces this for patients with T2D and concomitant HF or CKD. The CCS guidance supports SGLT2i initiation at eGFR > 30 mL/min/1.73m² for cardiorenal protection, a threshold that has expanded meaningfully from earlier prescribing restrictions.

The Diabetes Canada 2024 Quick Reference Guide is a single-page printable reference that summarizes the cardiorenal algorithm, A1C targets, SGLT2i eGFR thresholds, lipid targets, and the updated position on ASA (no longer recommended for primary prevention). It belongs on the wall of every BC clinic managing T2D patients.

The Risk You're Missing: Sudden Cardiac Death and Screening Gaps

Two 2025 studies add important nuance to how cardiovascular risk should be communicated and acted upon in T2D practice.

The first, a Danish population-based study in the European Heart Journal, quantified the risk of sudden cardiac death (SCD) in people with diabetes. The findings are stark: T2D confers a 6.5-fold increased risk of SCD compared to no diabetes, and this risk was observed independently of established coronary artery disease. People with T2D are dying suddenly, without prior warning, at dramatically elevated rates. This is not a complication confined to patients with known heart disease.

The second, published in JACC: Advances, found that nearly half of patients presenting with their first myocardial infarction had low or borderline ASCVD risk scores prior to their event. Standard risk calculators, including the Framingham Risk Score and the newer AHA PREVENT tool, failed to identify many at-risk individuals under age 66. Sixty percent of patients did not develop symptoms until within 48 hours of their cardiac event.

Together, these findings send a consistent message: standard risk stratification underestimates cardiovascular risk in T2D. Waiting for a risk calculator to cross a threshold before initiating cardiorenal therapy is a strategy that will miss a substantial proportion of the patients most likely to benefit.

T2D itself should be treated as a high cardiovascular risk state, independently of calculated ASCVD score, and independently of current A1C.

The Prescribing Gap: Why the Evidence Isn't Translating

Despite overwhelming evidence and clear guideline recommendations, real-world prescribing data is sobering. A 2025 cross-sectional study found that fewer than 20% of newly diagnosed T2D patients with high cardiovascular risk or CKD received an SGLT2 inhibitor or GLP-1 receptor agonist within 3 months of diagnosis. This pattern, high evidence, low uptake, is consistent across jurisdictions and represents one of the most concrete gaps in contemporary diabetes care.

The barriers are documented and, for the most part, addressable: unfamiliarity with expanded indications, concern about cost and reimbursement, hesitancy about side-effect management, and the inertia of established prescribing patterns built around HbA1c targets. For BC providers, BC PharmaCare Special Authority criteria cover SGLT2 inhibitors and GLP-1 receptor agonists for high-risk patients – checking eligibility at the time of review is a practical first step.